Law360, New York (March 15, 2010, 1:45 PM ET) -- Ranbaxy Laboratories Ltd. has agreed to license Takeda Pharmaceutical Co. Ltd.'s Actos patents in order to end a protracted legal battle and bring a generic version of the blockbuster diabetes treatment to market.
India-based Ranbaxy announced Monday that Takeda had agreed to drop its infringement action in the U.S. District Court for the Southern District of New York and grant Ranbaxy a nonexclusive royalty-free license to the seven U.S. patents covering Actos, the brand name for pioglitazone hydrochloride.
Under the terms of the deal, Ranbaxy is...
Ranbaxy, Takeda Strike Licensing Deal Over Actos
To view the full article, take a free trial now.
